EM high yield has extended its 2025 momentum, delivering strong carry and compelling yields. With higher credit quality and lower defaults, the segment offers a more attractive risk profile than US high yield.

AI is reshaping innovation across biotech by accelerating drug discovery, improving genomics, and advancing precision medicine.

BDCs continue to offer some of the highest yields in private credit and pullbacks may allow investors to capture tax benefits while staying invested.